PREMARIN VAGINAL CREAM

Country: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

CONJUGATED ESTROGENS

থেকে পাওয়া:

PFIZER CANADA ULC

এটিসি কোড:

G03CA57

INN (International Name):

CONJUGATED ESTROGENS

ডোজ:

0.625MG

ফার্মাসিউটিকাল ফর্ম:

CREAM

রচনা:

CONJUGATED ESTROGENS 0.625MG

প্রশাসন রুট:

VAGINAL

প্যাকেজ ইউনিট:

162

প্রেসক্রিপশন টাইপ:

Prescription

Therapeutic area:

ESTROGENS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0106442005; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2010-09-17

পণ্য বৈশিষ্ট্য

_Premarin_
_®_
_ Vaginal Cream _
_Page 1 of 40 _
COMPLETE PRESCRIBING INFORMATION
Pr
PREMARIN
®
Vaginal Cream
(Conjugated Estrogens CSD, 0.625 mg/g)
ESTROGENIC HORMONES
®
Pfizer Canada Inc.
17,300 Trans-Canada Highway
Kirkland, QC H9J 2M5
Date of Revision:
June 2, 2017
Submission Control No: 204671
_Premarin_
_®_
_ Vaginal Cream _
_Page 2 of 40 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
...........................................................................3
INDICATIONS AND CLINICAL USE
................................................................................3
CONTRAINDICATIONS
......................................................................................................3
WARNINGS AND PRECAUTIONS
....................................................................................4
ADVERSE REACTIONS
....................................................................................................13
DOSAGE AND ADMINISTRATION
................................................................................20
OVERDOSAGE
...................................................................................................................21
ACTION AND CLINICAL PHARMACOLOGY
...............................................................22
STORAGE AND STABILITY
............................................................................................24
SPECIAL HANDLING INSTRUCTIONS
..........................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................24
PART II: SCIENTIFIC INFORMATION
...............................................................................26
PHARMACEUTICAL INFORMATION
............................................................................26
CLINICAL TRIALS
............................................................................................................27
DETAILED